AnnJi Pharmaceutical's AJ201 Advances to Pivotal Phase 3 Trial for Rare Muscle Atrophy Disease

AnnJi Pharmaceutical's Progress with AJ201 in SBMA Treatment

AnnJi Pharmaceutical Co., Ltd. (TPEx 7754), a company dedicated to developing innovative small molecules, is taking significant strides in combating Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease. Their latest announcement, made on October 5, 2026, reveals the progression of AJ201 (Rosolutamid) into the pivotal Phase 3 trial known as "ROMA-KD". This move responds to the urgent need for effective treatment options for this debilitating hereditary neuromuscular disorder, which currently lacks FDA-approved therapies.

Understanding SBMA

SBMA is a rare genetic disease caused by the expansion of CAG repeats in the androgen receptor gene (AR), leading to the degeneration of motor neurons and muscles. This progressive condition manifests in various daily challenges: climbing stairs becomes more daunting, swallowing food becomes increasingly difficult, and maintaining communication through voice becomes a struggle. Affected individuals often face intricate fears connected to their genetic heritage, as SBMA can affect multiple generations within a family.

Advancing AJ201: A Breakthrough Approach

AJ201 is an oral, low-molecular-weight drug aimed at addressing multiple disease mechanisms involved in SBMA. It works by promoting the degradation of the pathogenic mutated androgen receptor protein (mAR) and activating cellular stress response pathways, particularly Nrf1, Nrf2, and HSF1. The drug has gained recognition from the FDA, receiving both "Fast-Track" designation and "Orphan Drug" status, signifying its potential to significantly impact public health in the context of this rare disease.

The Phase 3 study builds upon promising results from the recently completed Phase 2 trial held in May 2025. The ROMA-KD study is designed as a global, multicentric, randomized, double-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of AJ201 in ambulatory patients with symptomatic SBMA. With an expected enrollment of approximately 200 patients worldwide, the United States is anticipated to represent a crucial region for the trial.

Engagement with the SBMA Community

Dr. Wendy Huang, the Chair and CEO of AnnJi, emphasized the significance of this development, stating, "The transition of AJ201 into Phase 3 brings us a step closer to potentially changing the lives of those living with SBMA. We are committed to activating study centers in the U.S. and responsibly completing this study in collaboration with affected patients and their families."

To deepen their commitment, AnnJi has established a Patient and Care Partner Advisory Board in collaboration with the Kennedy's Disease Association (KDA). This initiative provides a forum for continuous dialogue between AnnJi and the SBMA community, incorporating personal experiences of those living with the condition to inform patient-centered research and clinical development.

The Path Ahead

With no current FDA-approved treatment for SBMA, AJ201 represents a glimmer of hope for those affected by this condition. AnnJi's continued dedication to advancing AJ201 reflects their broader goal of developing therapies that enhance the quality of life for patients facing neglected chronic illnesses.

As they move forward, the company is poised to work transparently with patients, care partners, doctors, and advocacy groups, ensuring that their efforts resonate deeply with the community they aim to serve. AnnJi's vision remains rooted in creating effective solutions that address significant medical needs, thus representing a potential turning point in the fight against SBMA.